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Summary  A  50-year-old  man  diagnosed  with  liver  cirrhosis  type  C  was  referred  to  our  hos-
pital  because  of  right  heart  failure  with  pulmonary  hypertension.  Echocardiography  revealed
enlargement  of  the  right  atrium  and  ventricle  with  severe  tricuspid  regurgitation.  The  peak  ﬂow
velocity  of  tricuspid  regurgitation  by  continuous  wave  Doppler  echocardiography  was  452  cm/s.
Right  heart  catheterization  demonstrated  severe  pulmonary  hypertension  [pulmonary  arte-
rial  pressure  (PAP)  systolic/diastolic/mean  =  73/20/41  mmHg  and  pulmonary  vascular  resistance
(PVR)  =  509  dyn  s  cm—5]  with  portal  hypertension.  We  diagnosed  the  patient  as  having  portopul-
monary hypertension  (PoPH).  Although  we  treated  the  patient  with  a  prostacyclin  analog,
tricuspid regurgitation  velocity  was  increased  to  480  cm/s  four  years  after  the  start  of  the
therapy.  To  select  drugs  for  the  treatment  of  PoPH,  we  performed  an  acute  vasoreactivity  test
of  sildenaﬁl  during  right  heart  catheterization.  Since  single  administration  of  sildenaﬁl  (20  mg)
decreased  PAP  (93/30/55—77/27/44  mmHg)  and  PVR  (908—833  dyn  s  cm—5),  we  added  sildenaﬁl
(20  mg,  t.i.d.)  to  the  prostacyclin  analog.  Tricuspid  regurgitation  velocity  decreased  to  403  cm/s
one  year  after  the  addition  of  sildenaﬁl.  An  acute  vasoreactivity  test  of  sildenaﬁl  during  right
heart  catheterization  was  useful  for  the  decision  of  the  drug  to  be  used  in  the  treatment  of
PoPH.
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doi:10.1016/j.jccase.2011.04.001ntroductionortopulmonary  hypertension  (PoPH)  is  a  rare  and  refrac-
ory disease.  Although  new  drugs  have  become  available
or speciﬁc  treatment  of  pulmonary  arterial  hypertension,
reatment of  PoPH  has  not  been  established.  An  acute
Published by Elsevier Ltd. All rights reserved.
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Figure  1  Transthoracic  echocardiography.  Left  panels:  four  years  after  the  start  of  treatment  with  a  prostacyclin  analog  and
before  sildenaﬁl  treatment.  Right  panels:  one  year  after  the  addition  of  sildenaﬁl.  Parasternal  short-axis  view  recorded  in  diastole
(A  and  D)  and  end-systole  (B  and  E).  Tricuspid  regurgitation  velocity  (C  and  F).  Four  years  after  the  start  of  prostacyclin  analog
treatment  before  sildenaﬁl  treatment,  left  ventricle  was  D-shaped  during  systole  and  end-diastole  due  to  the  enlargement  of  the
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Wight  ventricle.  Tricuspid  regurgitation  velocity  was  480  cm/s.  
as  improved  and  tricuspid  regurgitation  velocity  decreased  to
ulmonary  vasoreactivity  test  has  been  used  for  decision  of
he treatment  in  idiopathic  pulmonary  arterial  hypertension
1]. However,  the  usefulness  of  the  test  in  PoPH  has  not  been
eported. We  present  a  case  in  which  an  acute  vasoreactiv-
ty test  of  sildenaﬁl,  a  phosphodiesterase-5  inhibitor,  was
seful in  the  treatment  of  PoPH.
ase report
 50-year-old  man  was  diagnosed  with  liver  cirrhosis  type  C
n  2003.  Pulmonary  hypertension  (PH)  was  not  detected  at
hat time.  He  was  referred  to  our  hospital  in  2004  because
f right  heart  failure  with  PH.  Echocardiography  showed
nlargement of  the  right  atrium  and  ventricle  with  ventricu-
ar septum  ﬂattening  during  systole.  The  peak  ﬂow  velocity
f tricuspid  regurgitation  by  continuous  wave  Doppler
chocardiography was  452  cm/s.  Right  heart  catheteriza-
ion demonstrated  severe  PH  [pulmonary  artery  pressure
S
a
v
vyear  after  the  addition  of  sildenaﬁl,  D-shape  of  left  ventricle
cm/s.
PAP)  systolic/diastolic/mean  =  73/20/41  mmHg,  pulmonary
ascular resistance  (PVR)  =  509  dyn  s  cm—5]  with  the  ele-
ation of  portal  pressure  [portal  pressure  of  12  mmHg
normal <  11  mmHg)].  Results  of  pulmonary  arteriography
nd oxymetry  were  normal.  A  pulmonary  perfusion  scinti-
ram did  not  suggest  the  presence  of  thromboembolism.
 blood  examination  showed  elevations  of  total  biliru-
in (2.1  mg/dl),  aspartate  aminotransferase  (63  IU/L),  brain
atriuretic peptide  (BNP)  (219  pg/mL),  and  reduction  of
latelet count  (4.0  ×  104/L).  Anti-DNA  antibody  and  anti-
NP antibody  levels  were  slightly  elevated.  However,
ollagen disease  was  excluded  as  the  cause  of  PH  because
f the  absence  of  other  collagen-related  ﬁndings.  According
o these  ﬁndings,  we  diagnosed  the  patient  as  having  PoPH.
e started  to  treat  the  patient  with  a  prostacyclin  analog.
ince right  heart  failure  had  occurred  in  2007,  we  added
n inotropic  agent,  pimobendan.  However,  D-shaped  left
entricle progressed  (Video  1)  and  tricuspid  regurgitation
elocity increased  to  480  cm/s  in  2008  (Fig.  1A—C).  To  select
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Table  1  Response  to  single  administration  of  sildenaﬁl  at  right  heart  catheterization.
HR  BP  (s/d/m)  PAP  (s/d/m)  CI  PVR
Baseline  90  112/65/82  93/30/50  2.4  908
After  1  h  92  110/62/78  87/27/47  —  —
After 2  h  87  116/66/83  82/27/45  —  —
After 3  h  87  115/63/81  77/27/44  2.3  833
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[HR, heart rate (1/min); BP, noninvasive blood pressure (mmHg); s/d
CI, cardiac index (l/min/m2); PVR, pulmonary vascular resistance
drugs  for  the  treatment  of  PoPH,  we  performed  an  acute
vasoreactivity test  of  sildenaﬁl  during  right  heart  catheter-
ization. Since  single  administration  of  sildenaﬁl  (20  mg)
decreased PAP  and  PVR  without  reduction  of  blood  pressure
(BP) and  cardiac  index  (CI)  after  3  h  (Table  1),  we  added
sildenaﬁl (20  mg  t.i.d.)  to  the  prostacyclin  analog.  One  year
after the  addition  of  sildenaﬁl,  he  had  no  signs  of  deteri-
oration of  clinical  symptoms  in  right  heart  failure  and  PH
such as  dyspnea,  general  fatigue,  and  leg  edema.  The  level
of BNP  was  10.5  pg/mL.  Echocardiography  showed  that  D-
shaped left  ventricle  was  improved  (Video  2)  and  tricuspid
regurgitation velocity  decreased  to  403  cm/s  one  year  after
the addition  of  sildenaﬁl  (Fig.  1D—F).
Discussion
PoPH  is  deﬁned  as  the  elevation  of  mean  PAP  (25  mmHg)
and  PVR  (240  dyn  s  cm—5),  normal  pulmonary  capillary
wedge pressure  (15  mmHg),  and  presence  of  portal  hyper-
tension  [2].  Portal  hypertension,  rather  than  the  presence  of
underlying liver  disease,  is  important  for  the  development  of
PoPH [2,3].  Medial  hypertrophy  and  plexiform  lesion  in  the
pulmonary artery  are  hallmarks  of  PoPH  as  well  as  idiopathic
pulmonary arterial  hypertension  [4].  Long-term  prognosis
has been  shown  to  be  related  to  the  presence  and  severity
of liver  cirrhosis  and  to  cardiac  function  [5].  Results  of  sev-
eral studies  on  PoPH-speciﬁc  therapies  including  intravenous
administration of  epoprostenol,  bosentan,  and  sildenaﬁl  in
patients with  PoPH  have  been  published  [5—7].  Although
there is  no  consensus  on  the  treatment  of  PoPH  [8],  silde-
naﬁl is  thought  to  have  an  advantage  for  the  oral  treatment
of PoPH  because  there  is  a  low  risk  of  hepatotoxicity  and  the
treatment is  noninvasive.
An acute  pulmonary  vasoreactivity  test  of  sildenaﬁl  in
PoPH has  not  been  reported,  although  it  has  been  reported
in idiopathic  pulmonary  arterial  hypertension  [9].  In  the
present case,  we  evaluated  the  hemodynamic  response  to
the single  administration  of  sildenaﬁl  during  right  heart
catheterization. Since  single  administration  of  sildenaﬁl
decreased PAP  and  PVR  without  reduction  of  BP  and  CI,
we decided  to  treat  the  patient  with  sildenaﬁl.  The  treat-
ment with  sildenaﬁl  improved  PoPH  one  year  after  the  start
[systolic/diastolic/mean; PAP, pulmonary artery pressure (mmHg);
 s cm—5).
f  therapy.  Although  PoPH  is  often  resistant  to  therapy,  an
cute vasoreactivity  test  of  sildenaﬁl  is  useful  for  determin-
ng the  choice  of  drugs  in  the  treatment  of  PoPH.
ppendix A. Supplementary data
upplementary  data  associated  with  this  arti-
le can  be  found,  in  the  online  version,  at
oi:10.1016/j.jccase.2011.04.001.
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